DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma)

DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma) - DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031220

Enrollment

300

Registered

2018-02-09

Start date

2017-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with recurrent or refractory multiple myeloma who received DARZALEX

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness	—

Countries

Japan

Contacts

Public ContactHirokazu Shirai

Janssen Pharmaceutical K.K. Medical Affiars Delivery Unit

hshirai3@ITS.JNJ.com03-4411-5136

Outcome results